Entrar Registro gratuito

RepliCel Life Sciences EBITDA

Qual é o EBITDA de RepliCel Life Sciences?

O EBITDA de RepliCel Life Sciences, Inc. é -CAD$1.84

Qual é a definição de EBITDA?



O EBITDA é o lucro de uma empresa antes de juros, impostos, depreciação e amortização e é uma medida contábil calculada com base no lucro líquido de uma empresa, subtraído antes das despesas de juros, impostos, depreciação e amortização, como imagem da lucratividade operacional corrente de uma empresa.

Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.

EBITDA de empresas na Setor Health Care em TSXV em comparação com RepliCel Life Sciences

O que RepliCel Life Sciences faz?

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.

Empresas com ebitda semelhantes a RepliCel Life Sciences